|
- label - Food and Drug Administration
Subcutaneous Injection for UC ENTYVIO prefilled syringe and ENTYVIO PEN are intended for subcutaneous use under the guidance and supervision of a healthcare professional Patients or caregivers may self-inject subcutaneous ENTYVIO using either the ENTYVIO prefilled syringe or ENTYVIO PEN after training in subcutaneous injection technique
- ENTYVIO® (vedolizumab) - Official HCP Website
Learn more about ENTYVIO® (vedolizumab), a biologic treatment for moderate to severe ulcerative colitis or Crohn's disease in adults
- Entyvio PI - Takeda Pharmaceutical Company
Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist
- ENTYVIO® (vedolizumab) Instructions for Use
Single-dose prefilled pen This Instructions for Use contains information on how to inject ENTYVIO
- Entyvio (Takeda Pharmaceuticals America, Inc. ): FDA Package . . .
Takeda Pharmaceuticals America, Inc : ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC) moderately to severely active Crohn's disease (CD) ENTYVIO is an integrin
- FDA Label for Entyvio Injection, Powder, Lyophilized, For . . .
Insert the syringe needle into the vial through the center of the stopper and direct the stream of Sterile Water for Injection to the glass wall of the vial to avoid excessive foaming Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder Do not vigorously shake or invert
- HIGHLIGHTS OF PRESCRIBING INFORMATION . . .
These highlights do not include all the information needed to use ENTYVIO safely and effectively See full prescribing information
- PRODUCT MONOGRAPH PrENTYVIO
Subcutaneous maintenance treatment Entyvio® was studied in a double-blind, placebo-controlled clinical study in 383 enrolled patients with ulcerative colitis who received maintenance treatment with 108 mg subcutaneous Entyvio® every other week
|
|
|